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A B S T R A C T
Objectives: Disease-modifying therapies (DMTs) reduce relapse rates and disability progression for relapsing multiple scle-
rosis (MS). Although 25% to 30% of all US patients with MS are Medicare beneficiaries, limited information exists on this
population. This is the first study using national Medicare data to (1) describe characteristics of patients with MS using DMTs,
(2) estimate adherence to DMTs over a 1-year and 3-year follow-up, and (3) examine factors associated with DMT adherence.
Methods: This retrospective claims analysis used 2011-2014 100% Medicare files. Monthly adherence to MS DMTs was defined
as the proportion of days covered $0.80 with any DMT in each month for 1-year (n = 36 593) and 3-year (n = 17 599) follow-
up samples of MS DMT users. Generalized estimating equation logistic regressions were used to estimate factors associated
with adherence to DMTs.
Results: Over 90% of patients were eligible for Medicare owing to disability, and about three-quarters qualified for low-income
subsidies. A downward trend in DMT adherence was observed over time in both samples. Monthly adherence dropped
significantly between December of the prior year to January of the following year (from 76% to 65% in the 1-year follow-
up sample and similar drops seen across all years in the 3-year follow-up sample). Multivariable regressions indicated
characteristics such as being low-income, having a disability, and having high patient out-of-pocket DMT costs associated
with poor adherence to DMTs.
Conclusion: Our study provides important insights into the characteristics and DMT adherence of Medicare patients with MS
and highlights the need for interventions and policies mitigating barriers to adherence in this population.
Keywords: adherence, administrative claims data, disease-modifying therapies, multiple sclerosis, Medicare.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, disabling
autoimmune disease of the central nervous system affecting
approximately 1 million Americans.1,2 Approximately 85% of in-
dividuals with MS are initially diagnosed with the relapsing-
remitting form of the disease, which is characterized by acute
exacerbations or relapses (eg, problems with vision, balance, gait,
or speech).3,4 Although there exists no curative treatment for
relapsing-remitting MS, disease-modifying therapies (DMTs) have
been shown to reduce relapse rates, slow disease progression, and
delay disability; thereby constituting the primary treatment for
relapsing forms of MS.5 Achieving therapeutic goals through DMTs
requires patients to be adherent to their prescribed therapy. As
with most therapies for chronic conditions, patient adherence to
DMTs has been reported to be suboptimal in the United States.6
Nevertheless, most of these studies have been conducted in pri-
vately insured patients.6-13
Limited information exists on patients with MS covered by
Medicare, a federally funded health insurance program for elderly
individuals or individuals with a disability in the United States.
This is a glaring gap in the literature because it has been estimated
that 25% to 30% of all patients with MS in the United States are
covered under Medicare.14-16 There are several additional reasons
to examine the Medicare patients with MS. Medicare patients are
typically excluded from MS clinical trials of DMTs owing to their
age or disability. Hence, a better understanding of the character-
istics of Medicare patients with MS who are using DMTs and their
real-world treatment utilization patterns is an important first step
prior to evaluation of clinical outcomes associated with DMT use
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in this population. In addition, unlike privately insured patients,
once enrolled, patients are covered under Medicare throughout
their lifetime. Thus, identification of suboptimal adherence and
associated factors has the potential to inform targeting of Medi-
care policies and quality improvement efforts to improve long-
term clinical outcomes (eg, disability progression) and health-
care spending in this population.
This study is the first to use data from a national sample of
Medicare patients to (1) describe characteristics of beneficiaries
with MS using DMTs; (2) estimate adherence to DMTs over a
1-year and 3-year longitudinal follow-up; and 3) examine de-




Data on patients with MS using DMTs at any time during 2011
to 2014 were extracted from the Chronic Conditions Data Ware-
house 100% Medicare files available from the Centers for Medicare
& Medicaid Services. The Chronic Conditions Data Warehouse
database includes Medicare Part A and Part B medical claims for
inpatient care, skilled nursing facility care, home health services,
outpatient services, durable medical equipment, and hospice
services as well as Part D prescription claims files for outpatient
prescription drug events for fee-for-service Medicare benefi-
ciaries. These files were linked to personal summary files that
contained patient demographics and eligibility information and
Part D plan characteristics files. Part D plan characteristics files
included information such as the plan premium, type of plan (eg,
Prescription Drug Plans and Medicare Advantage Prescription
Drug Plans), and type of benefit (eg, standard, enhanced
alternative).
Study Design and Sample
This was a retrospective administrative claims analysis exam-
ining patient characteristics and DMT adherence among 1-year
and 3-year follow-up samples of patients with MS using DMTs.
The DMTs available during the study period and included in the
study are listed in Appendix Table 1 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.10.011. The sampling
frame consisted of person-year observations of beneficiaries with
fee-for-service Medicare coverage who were enrolled in a stand-
alone Part D plan and had evidence of DMT use in any year be-
tween 2011 and 2014. Next, we created 2-year segments over any
2 consecutive year period (2011-2012, 2012-2013, 2013-2014)
wherein the first year in the 2-year segment was referred to as the
baseline year, and the second year was referred to as the follow-up
year. Two-year segments for our 1-year follow-up sample were
selected for DMT users with 12-month Medicare fee-for-service
and standalone Part D coverage and $1 inpatient or $2 outpa-
tient claims with a diagnosis of MS (International Classification of
Diseases, ninth revision, Clinical Modification code 340.xx) in the
baseline year who additionally met the following criteria: (1) $1
claim for any DMT in the last quarter of the baseline year to ensure
recent use before the follow-up period for measuring outcomes,
(2) 12-month continuous fee-for-service Medicare and Part D
coverage and alive in the follow-up year, (3) not in hospice in the
follow-up year, (4) with 12-month full low-income subsidy (LIS) or
non-LIS (Medicare beneficiaries not qualifying for Part D LIS)
status in the follow-up year, and (5) with no missing data points or
covariates necessary for the study. For each patient, the earliest
2-year segment for which they met eligibility criteria was selected
for inclusion in the final 1-year follow up sample. For example, if
patients met the eligibility criteria for three 2-year segments
(2011-2012, 2012-2013, and 2013-2014), only 2011-2012 segment
was selected. The 3-year follow-up sample was a subsample of our
1-year follow-up sample with an additional requirement of
continuous 3-year Medicare fee-for-service and standalone Part D
coverage during the follow-up period.
Outcome Measures
The primary outcome of interest was monthly adherence to
any MS DMT, which allows examination of changes in adherence
by month. Monthly adherence to the MS DMTs was defined as the
proportion of days covered (PDC) with any DMT (Part B or Part D)
in each month.12 The PDC was measured as the number of days
covered with any DMT divided by a fixed time interval (eg, 30
days) from the start of the period (eg, the first date of a month).
For example, a patient with MS having DMT coverage available for
24 days during the 30-day period would have a PDC of 24/30 =
0.80. A PDC $ 0.80 was deemed as adherent.17,18 In sensitivity
analysis, we defined adherence as PDC $ 0.7 or PDC $ 0.9. The
DMTs for MS that are infused or administered under medical su-
pervision (eg, natalizumab) fall under Medicare’s Part B medical
benefit and do not have a “days’ supply” data field. Therefore, the
days’ supply for Part B DMTs was assigned using its recommended
dosage regimen.19 Additionally, the PDC was adjusted to not
account for the days of hospital or skilled nursing facility stay in its
calculation to avoid underestimating PDC among such patients.20
Thus, any day a patient spent in a hospital or skilled nursing
facility was removed from the numerator and denominator of the
PDC because patients may have received their medication in the
facility.
Covariates
The covariates of interest in this study included a set of soci-
odemographic, clinical, and Part D plan benefit-related variables.
Sociodemographic variables included Medicare entitlement
reason (aged $65 years, aged $65 years but originally eligible as
disabled, and disabled under age 65 years), beneficiary age, sex,
race/ethnicity, census region of residence, and per-capita income
in the beneficiary’s county of residence. Clinical variables included
the prescription drug hierarchical condition category (RxHCC) risk
score,21 which has been used to adjust for potential selection
biases in drug use studies among Medicare patients,22,23 and the
presence of any all-cause hospitalization in the baseline year.
Specific variables related to MS clinical burden were also
measured, including the number of MS symptoms (bowel
dysfunction, cognitive dysfunction, depression or anxiety, double
vision, fall, fatigue, gait dysfunction, chronic pain, seizures, spas-
ticity, tremor, urinary incontinence, vision loss, etc), use of assis-
tive devices for mobility identified from the durable medical
equipment claims, and number of MS relapses24 in the baseline
year. In addition, our models included indicators for index year
(1-year follow-up model) or the follow-up year (3-year follow-up
model). Part D prescription drug plan benefit-related variables
included Medicare Part D plan type (defined standard benefit,
actuarially equivalent standard, basic alternative, and enhanced
alternative), Medicare Part D LIS status (full LIS vs non-LIS), and
Part D benefit phase defined by level of cost sharing (ie, patient
out-of-pocket costs). For the latter, each person-month observa-
tion was coded as being in a high Part D cost-sharing phase
(ie, deductible, initial coverage, or coverage gap phase) or low Part
D cost-sharing phase (ie, catastrophic phase). Owing to the Part D
subsidy, full LIS patients face substantially lower out-of-pocket
costs than non-LIS patients in all Part D cost-sharing phases.20
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Given the differences in the levels of cost sharing between these
groups, the regression models also included a covariate for an
interaction term between Part D low-income subsidy status and
Part D cost-sharing phase.
Statistical Analysis
Descriptive sample characteristics for the 1-year and 3-year
follow-up samples were generated. The proportion of patients
adherent (PDC $ 0.80) to any DMT in each month was plotted
over 1-year and 3-year follow-up. Multivariable generalized esti-
mating equation logit regressions adjusting for repeated measures
were used to examine factors associated with being adherent to
any DMT using the person-month data for the 1-year and 3-year
follow-up sample. In addition, we conducted 2 sets of subgroup
analyses, namely among patients who had an MS relapse in the
baseline year and patients who had a disability under age 65
years. We also conducted a series of sensitivity analyses. We reran
models based on 2 alternative definitions of being deemed
adherent (PDC $ 0.70 or PDC $ 0.90 instead of PDC $ 0.80 in the
main analysis). Additional sensitivity analyses were conducted
wherein the outcome variable was re-specified as adherence to
Part D–covered DMTs (as opposed to any [Part D– or Part B–
covered] DMTs in the main analysis). All models accounted for
clustering owing to repeated observations per patient. The blinded
institutional review board deemed the study exempt from
informed consent procedures because no data were collected
directly from patients.
Results
The final sample with at least 1 year of follow-up consisted of
36 593 patients with MS using any DMT (see Appendix Fig. 1 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.201
9.10.011). Within our 1-year follow-up sample, 18% were elderly, of
which half were originally entitled to Medicare owing to disability
but were now over age 65 (Table 1). The remaining 82% of the
sample were those with a disability aged under 65, with most
between ages 45 and 64. The sample was predominantly female
(77%) and white (79%). In clinical characteristics, almost one-
quarter of the sample had an all-cause hospitalization, 18% had a
claim for 1 or more assistive devices for mobility needs, and 26%
had at least 1 MS relapse in the baseline year. Most patients were
enrolled in an actuarially equivalent standard benefit plan or basic
alternative plan under Medicare Part D. About 72% of our sample
qualified for full LIS status under Medicare Part D. On average, full
LIS patients paid $4 and $0, and non-LIS patients paid $1338 and
$220 per 30-day supply of Part D DMTs in the high cost-sharing
and low-cost sharing phases, respectively (data not shown).
Similar characteristics were reported in the 3-year follow-up
sample (n = 17 599, Table 1).
Figure 1 presents the percentage of patients adherent to MS
DMTs for each month in the 1-year and 3-year follow-up samples.
A significant drop in rates of being adherent was observed in
January (from 76% in December of baseline year to 65% in the
1-year follow-up sample, and 78% in December of baseline year to
67% in the first year of the 3-year follow-up sample). Similarly,
drops were observed consistently between December and January
even for the second and third years of follow-up in the 3-year
follow-up sample. Although adherence rates climbed in
February, they did not reach the levels observed in the months
before January. In addition, there was a downward trend of DMT
adherence in the 3-year follow-up sample (annual adherence rates
dropped from 64% in first year to 59% in the third year; data not
shown).
The multivariable analysis of factors associated with being
adherent is shown in Table 2. In the 1-year follow-up sample,
several sociodemographic factors were associated with the odds of
being adherent. Disability as the current or original Medicare
entitlement reason was associated with lower odds of being
adherent across all age categories. Men had higher odds than
women (OR 1.15; 95% CI:1.11-1.19), and black patients had lower
Table 1. Sample characteristics of Medicare beneficiaries with








(n = 17 599)
Sociodemographic characteristics
Age, mean (SD) 52.0 (11.8) 52.2 (11.6)
Medicare entitlement reason (%)
Aged $65, original entitlement
to Medicare not due to
disability
3311 (9) 1409 (8)
Aged $65, original entitlement
to Medicare due to
disability
3235 (9) 1624 (9)
Disabled under age 65 y 30 047 (82) 14 566 (83)
,34 y 2925 (8) 1284 (7)
35-44 y 7074 (19) 3319 (19)
45-54 y 11 044 (30) 5447 (31)
55-64 y 9004 (25) 4516 (26)
Sex (%)
Female 28 072 (77) 13 616 (77)
Male 8521 (23) 3983 (23)
Race (%)
White 28 955 (79) 14 150 (80)
Black 5809 (16) 2575 (15)
Latino and others 1829 (5) 876 (5)
Region (%)
Northeast 8078 (22) 4159 (24)
Midwest 10 503 (29) 5050 (29)
South 11 997 (33) 5575 (32)
West 6015 (16) 2815 (16)
Per-capita income in $10 000s in
county of residence, mean (SD)
4.2 (1.1) 4.1 (1.1)
Clinical characteristics
RxHCC, mean (SD) 1.7 (0.4) 1.7 (0.4)
Any inpatient stay in baseline
year (%)
8491 (23) 3996 (23)
Number of multiple sclerosis
symptoms, mean (SD)
2.2 (1.8) 2.2 (1.8)
Use of assistive device(s) for
mobility (%)
6424 (18) 3130 (18)
Number of relapses in baseline
year, %
0 27 119 (74) 13 071 (74)
1 6305 (17) 2969 (17)
$2 3169 (9) 1559 (9)
Part D prescription benefit characteristics
Part D plan type (%)
Actuarially equivalent standard 16 062 (44) 6973 (40)
Basic alternative 11 018 (30) 6202 (35)
Defined standard benefit 3343 (9) 1947 (11)
Enhanced alternative 6170 (17) 2477 (14)
Part D LIS status (%)
Full LIS 26 429 (72) 13 168 (75)
Non-LIS 10 164 (28) 4431 (25)
Note. All patients in 3-year follow-up sample have index year of 2012. Data
source: 2011-2014 Chronic Conditions Data Warehouse 100% Medicare files.
Data are n (%) or mean (SD).
LIS indicates low-income subsidies under Medicare Part D; RxHCC, prescription
drug hierarchical condition category risk score.
330 VALUE IN HEALTH MARCH 2020
odds of being adherent compared to white patients (OR 0.92; 95%
CI: 0.89-0.96). For clinical factors, patients with a higher RxHCC
score and having an inpatient stay in the baseline year had lower
odds of being adherent. Interestingly, patients with MS relapses in
the baseline year had lower odds of being adherent in the follow-
up year. For Part D benefit design factors, patients in plans with
the standard Part D benefit or plans that offered a basic alternative
or actuarially equivalent to standard benefit design had lower
odds of being adherent than patients in the more generous
enhanced alternative Part D plans. Being in the high cost-sharing
phase was associated with lower odds of being adherent than in
the low cost-sharing phase. Although non-LIS status under
Medicare Part D was associated with higher odds of being
adherent than LIS status during the low cost-sharing phase (OR
1.47; 95% CI: 1.41-1.54), the high cost-sharing phase had a larger
negative impact on non-LIS patients than on LIS patients as evi-
denced by the statistically significant lower odds ratio on the
interaction term (OR 0.55; 95% CI: 0.53-0.57).
Multivariable analysis of the 3-year follow-up sample had
similar results as those observed in the 1-year follow-up sample
with the exception that the Medicare entitlement reasons and
race no longer had statistically significant associations with the
odds of being adherent (Table 2). Of note with this longitudinal
sample was the decline in adherence over the 3 years of follow-up
as evidenced by the result that patients had lower odds of being
adherent during the second year (OR 0.82; 95% CI:0.81-0.83) and
third year (OR 0.75; 95% CI: 0.74-0.76) of follow-up compared to
the first year.
Consistent with main results, our subgroup analysis of patients
with an MS relapse in the baseline year (see Appendix Table 2 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.201
9.10.011) and patients with a disability under age 65 years (see
Appendix Table 3 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2019.10.011) and all our sensitivity analysis (see
Appendix Tables 4 and 5 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2019.10.011) found that male and
non-LIS statuses were associated with higher adherence and a
higher RxHCC score, and being in the high cost-sharing phase was
associated with lower odds of being adherent than in the low cost-
sharing phase. Also, the high cost-sharing phase had a larger
negative impact on non-LIS patients than on LIS patients as evi-
denced by the statistically significant lower odds ratio on the
interaction term.
Discussion
This study is among the first to profile the characteristics of a
national sample of fee-for-service Medicare beneficiaries with
MS using DMTs and examine treatment adherence and associated
factors over longitudinal follow-up. An examination of this rela-
tively large group of patients with MS in the United States was
important because compared to their commercially insured
counterparts, this group is primarily composed of low-income
individuals with a disability. About nine out of ten Medicare
beneficiaries in our study were currently or previously eligible for
Medicare owing to disability (ie, after receiving disability benefits
from the Social Security Administration for at least 2 years).
Contrary to the common belief that Medicare patients with MS
are typically 65 years or older, our study finds that eight out of
Figure 1. Proportion of Medicare beneficiaries with multiple sclerosis adherent (PDC $ 0.80) to any disease-modifying therapy in each
month of follow-up (1-year and 3-year follow-up samples).
PDC indicates proportion of days covered.
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ten patients in the study were individuals with a disability
younger than age 65. Furthermore, three-quarters of the patients
qualified for low-income subsidies under Medicare Part D. The
remaining one-quarter of the patients who did not qualify as
low-income faced significant out-of-pocket costs for their
monthly DMT prescriptions ($220 to $1338). In addition to the
high level of disability and financial barriers faced by this
population, the burden of MS was also substantial; with one-
quarter of the patients having suffered an MS relapse in the
baseline year.
Table 2. Factors associated with being adherent (PDC $ 0.80) to any disease-modifying therapy among Medicare beneficiaries with
multiple sclerosis (1-year and 3-year follow-up sample).
Factors 1-year follow-up sample 3-year follow-up sample
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Sociodemographic characteristics
Medicare entitlement reason
Aged $65, original entitlement to Medicare not due to disability 1.00 (ref) - 1.00 (ref) -
Aged $65, original entitlement to Medicare due to disability 0.91 (0.85-0.98) .007 0.99 (0.91-1.08) .793
Disabled under age 65 y
,34 y 0.78 (0.72-0.84) ,.0001 0.97 (0.88-1.06) .486
35-44 y 0.82 (0.77-0.87) ,.0001 1.00 (0.92-1.08) .923
45-54 y 0.87 (0.82-0.93) ,.0001 1.01 (0.94-1.09) .791
55-64 y 0.93 (0.88-0.98) .010 1.05 (0.97-1.13) .228
Sex
Female 1.00 (ref) - 1.00 (ref) -
Male 1.15 (1.11-1.19) ,.0001 1.14 (1.09-1.19) ,.0001
Race
White 1.00 (ref) - 1.00 (ref) -
Black 0.92 (0.89-0.96) ,.0001 0.97 (0.92-1.02) .174
Latino and others 0.97 (0.91-1.04) .381 0.98 (0.91-1.06) .644
Region
Northwest 1.00 (ref) - 1$00 (ref) -
Midwest 0.98 (0.94-1.02) .322 0.96 (0.92-1.01) .129
South 0.98 (0.94-1.02) .251 0.95 (0.91-1.00) .064
West 0.96 (0.92-1.00) .068 0.97 (0.91-1.02) .262
Per-capita income in $10 000s in county of residence, mean (SD) 1.00 (0.99-1.01) .835 1.01 (1.00-1.03) .092
Clinical characteristics
RxHCC score 0.86 (0.83-0.89) ,.0001 0.90 (0.86-0.94) ,.0001
Any inpatient stay in baseline year 0.84 (0.81-0.87) ,.0001 0.88 (0.84-0.92) ,.0001
Total count of multiple sclerosis symptoms 1.00 (0.99-1.01) .862 0.98 (0.97-0.99) ,.0001
Use of assistive device(s) for mobility 1.01 (0.98-1.05) .441 0.98 (0.94-1.03) .472
Number of relapses in baseline year
0 1.00 (ref) - 1.00 (ref) -
1 0.96 (0.92-0.99) .021 0.97 (0.92-1.01) .158
$2 0.87 (0.83-0.91) ,.0001 0.88 (0$83-0$94) ,.0001
Part D prescription benefit characteristics
Part D plan type
Actuarially equivalent standard 0.94 (0.90-0.98) .006 0.95 (0.89-1.00) .069
Basic alternative 0.94 (0.90-0.98) .007 0.95 (0.90-1.00) .068
Defined standard benefit 0.89 (0.84-0.94) ,.0001 0.92 (0.86-1.00) .036
Enhanced alternative 1.00 (ref) - 1.00 (ref) -
Part D LIS status
Full LIS 1.00 (ref) - 1.00 (ref) -
Non-LIS 1.47 (1.41-1.54) ,.0001 1.5 (1.42-1.59) ,.0001
Part D cost sharing phase
Low cost-sharing phase 1.00 (ref) - 1$00 (ref) -
High cost-sharing phase 0.36 (0.35-0.36) ,.0001 0.31 (0.30-0.31) ,.0001
Interaction term for Part D LIS status and cost-sharing phase
Non-LIS* high cost-sharing phase 0.55 (0.53-0.57) ,.0001 0.57 (0.56-0.59) ,0.0001
Index year
2012 1.00 (ref) - N/A N/A
2013 0.89 (0.86-0.93) ,.0001 N/A N/A
2014 0.86 (0.82-0.89) ,.0001 N/A N/A
Follow-up year
1st year of follow-up N/A N/A 1.00 (ref) -
2nd year of follow-up N/A N/A 0.82 (0.81-0.83) ,.0001
3rd year of follow-up N/A N/A 0.75 (0.74-0.76) ,.0001
Note. All patients in 3-year follow up sample have index year of 2012. Data source: 2011-2014 Chronic Conditions Data Warehouse 100% Medicare files.
LIS indicates low-income subsidies under Medicare Part D; RxHCC, prescription drug hierarchical condition category risk score.
*PDC greater than or equal to 0.80 was deemed as adherent.
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Our estimates on DMT adherence are also among the first to be
generated in this vulnerable population and highlight that
adherence to DMTs in Medicare patients with MS appears to be
highly dynamic (and not static) in nature even within a 1-year
time frame. An examination of our monthly adherence rates in
the 1-year follow-up sample revealed a significant drop in the
adherence rate between December of the previous year and
January of the following year. Even more noteworthy was the
consistent finding of sharp declines in DMT adherence rates from
December to January across each of the 3 years in the 3-year
follow-up sample. These findings correspond with the transition
from the period with the lowest out-of-pocket costs to the period
with the highest out-of-pocket costs for DMTs in the year, given
the variable design of the annual Medicare Part D benefit (which
covers most DMTs), and were confirmed in our multivariable an-
alyses. Although monthly adherence rates increased in February
(as the out-of-pocket costs likely became lower in magnitude), it
did not return to the level in December of the prior year. Also,
regardless of the ups and downs between December and February,
adherence rates had an overall declining trajectory over the 3
years of follow-up. These findings suggest that adherence
programs and policies should not solely rely on cross-sectional
interventions, but rather long-term follow-up is required for sus-
tained DMT adherence in this population. Furthermore, clinicians
treating Medicare patients with MS should also be cognizant of
this within-year and across-year variability in DMT adherence and
inquire about adherence and related issues at each clinic visit.
Our examination of factors associated with MS DMT adherence
revealed both expected and novel findings. Consistent with
studies examining commercially insured populations,10,11 we
found that being male was associated with higher odds of being
adherent to MS DMTs. However, counter to previous studies that
have examined relapse as an outcome of nonadherence to
DMTs,6,25-27 our study indicates an association between having an
MS relapse in the baseline year and subsequent nonadherence to
DMTs in the follow-up years. This is a surprising finding since MS
patients with a recent relapse may be more cognizant of the po-
tential severity of the consequences associated with the risk of
relapse owing to nonadherence to DMTs, and associated tempo-
rary or permanent disability such as weakness, vision loss, or
cognitive dysfunction. Nevertheless, it is also likely that the
relapse was a consequence of nonadherence in the baseline or
prior years and is a proxy for patients who have ongoing problems
with DMT adherence. Regardless, these patients represent an
important high-risk subgroup to be targeted for understanding
barriers to and identifying solutions for adherence to DMTs in
daily clinical practice.
Other groups of patients deserving attention that were iden-
tified in our study represent underserved populations including
minorities (ie, blacks), those with a disability (ie, those qualifying
for Medicare due to disability), and low-income (ie, those quali-
fying for full low-income subsidies under Part D) patients, all of
whom were more likely to be non-adherent than their counter-
parts, despite controlling for other sociodemographic and clinical
characteristics.
In addition to identifying several sociodemographic and clin-
ical risk factors for nonadherence that inform targeting of efforts
to improve DMT adherence in specific subgroups, our analyses
also identified important Part D benefit-related modifiable risk
factors. First, Medicare patients with MS who were enrolled in
Part D plans with enhanced (ie, generous) benefit designs were
more likely to be adherent than those who were enrolled in plans
with standard or actuarially equivalent alternative designs.
Although this finding could be a result of selection issues wherein
patients more likely to be adherent (or in higher need of DMTs)
chose enhanced plans, there is strong evidence suggesting most
Part D beneficiaries are choosing plans largely based on the
monthly premiums.28,29 Although monthly premiums may be
higher for the enhanced plans,30 other features of these plans
(such as supplemental cost-sharing, reduced deductible, or the
provision of coverage during the coverage gap/so-called donut
hole) may result in reduced prescription drug out-of-pocket costs
and support better adherence (and clinical outcomes) during the
year.30,31 Hence, there is a critical need for supporting tools and
education specifically tailored for patients with MS on the relative
costs and benefits of different Part D plan choices during the
annual open enrollment period. Second, we found that higher
drug out-of-pocket costs were significantly associated with lower
monthly DMT adherence rates. Unlike their commercial counter-
parts, Medicare beneficiaries’ cost-sharing requirements under
the Part D benefit design fluctuate during the year with out-of-
pocket costs highly concentrated at the beginning of the
year.32,33 While the impact of the high cost-sharing phase versus
the low cost-sharing phase under Part D was evidently negative
even in the full LIS patients who faced an average out-of-pocket
cost of $4 versus $0, respectively, it was even more negative in
non-LIS patients who faced average out-of-pocket costs of $1338
versus $220, respectively, per 30-day supply of Part D DMTs. These
results were even stronger in our sensitivity analysis where we
limited the adherence outcome specifically to Part D–covered
DMTs, which not only constituted most DMTs used in our sam-
ple but also were directly subject to the out-of-pocket costs under
the Part D benefit design. Prior work in non-LIS Medicare patients
with MS has shown that the month of January represents one-
third of the beneficiary’s annual Part D out-of-pocket spending
on DMTs,32,33 and the transition from the low cost-sharing phase
to the high cost-sharing phase can result in significant DMT
treatment interruptions of 30 days or longer (Li et al, 2018).20
Thus, our findings further add to this evidence base and fuel the
call for policy changes to alleviate the total out-of-pocket cost
burden under Part D and smooth out these costs over the year,
especially for patients needing specialty drugs like DMTs.32,33
Finally, our results also raise concern for commercially insured
patients who are also increasingly facing high deductibles in their
health plans and hence will have highly concentrated out-of-
pocket costs in the beginning of the year. Future research in
these patients is also needed since most studies in privately
insured patients are from a period when cost-sharing levels were
very low. 22
Our study findings should be interpreted in light of the
following limitations. First, although our PDC measure is a widely
used and accepted adherence measurement method with
administrative claims datasets,17 it does not reflect whether a
medication was actually taken as prescribed. Second, as is the case
with all administrative claims database studies, we did not have
information on the reasons for nonadherence to MS DMTs from
patients. Third, administrative claims databases are not developed
for research purposes and lack information on clinical parameters
(eg, disease severity, MS subtype). Hence, we were unable to
identify patients in our sample who progressed to secondary
progressive MS (which does not require the use of DMTs) over our
study period. Nevertheless, oftentimes in clinical practice, neu-
rologists treating patients with MS who become secondary pro-
gressive refrain from discontinuing use of DMTs.34 Fourth, claims
data are only available for the Medicare fee-for-service population,
and hence the study findings may not be generalizable to Medi-
care Advantage patients. Lastly, the scope of this study did not
include assessing the impact of DMT nonadherence on clinical
outcomes, health resource use, and costs. Nevertheless, evidence
from privately insured patients suggests that nonadherence to MS
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DMTs is associated with an increased risk of relapse and health
resource utilization.35,36 Future research should examine whether
similar findings are identified in the Medicare population.
Notwithstanding these caveats, our study provides insights into
an important but grossly understudied group of US Medicare pa-
tients with MS on DMT therapy with direct implications for clinical
practice and policy. Interventions and policies to mitigate barriers
to adherence are urgently needed to improve overall DMT adher-
ence and reduce the potentially harmful outcomes of MS relapses
and disability progression in this largely underserved population.
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